Personalized medicine: A competitor or an upgrade of evidence-based medicine?

Personalized Medicine

Volumn 9, Issue 2, 2012, Pages 211-221

  Bereczki, Daniel ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

biomarkers; clinical decision making; clinical trials; evidence based medicine; personalized medicine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; DIHYDROERGOTAMINE; PARACETAMOL; SULFANILAMIDE; WARFARIN;

CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONSULTATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ELIXIR; EVIDENCE BASED MEDICINE; GENOMICS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MEDICAL PRACTICE; MEDICAL PROFESSION; MEDICAL RESEARCH; MEDICAL TECHNOLOGY; PATIENT CARE; PATIENT COMPLIANCE; PATIENT PREFERENCE; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE; SYSTEMATIC REVIEW (TOPIC);

EID: 84858432024     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.11.93     Document Type: Review

References (71)

1. Goldhaber SZ. Optimal duration of anticoagulation after venous thromboembolism: fixed and evidence-based, or flexible and personalized? Ann. Intern. Med. 150, 644-646 (2009).
2. Basu S. Personalized versus evidence-based medicine with PET-based imaging. Nat. Rev. Clin. Oncol. 7, 665-668 (2010).
3. Tarantini G, Lanzellotti D. Three-vessel coronary disease in diabetics: personalized versus evidence-based revascularization strategy. Future Cardiol. 6, 797-809 (2010).
4. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 312, 71-72 (1996).
5. Miles A, Loughlin M, Polychronis A. Evidence-based healthcare, clinical knowledge and the rise of personalised medicine. J. Eval. Clin. Pract. 14, 621-649 (2008).
6. Chan IS, Ginsburg GS. Personalized medicine: progress and promise. Annu. Rev. Genomics Hum. Genet. 12, 217-244 (2011).
7. Ginsburg GS, Willard HF. Genomic and personalized medicine: foundations and applications. Transl. Res. 154, 277-287 (2009).
8. Smith CM. Origin and uses of primum non nocere - above all, do no harm! J. Clin. Pharmacol. 45, 371-377 (2005).
9. Geiger JC. Concerning elixir of sulfanilamide. Cal. West. Med. 47, 353 (1937).
10. Wax PM. Elixirs, diluents, and the passage of the 1938 Federal Food, Drug and Cosmetic Act. Ann. Intern. Med. 122, 456-461 (1995).
11. De Craen AJ, Kaptchuk TJ, Tijssen JG, Kleijnen J. Placebos and placebo effects in medicine: historical overview. J. R. Soc. Med. 92, 511-515 (1999).
12. Dunlop DM, Henderson TL, Inch RS. A survey of 17,301 prescriptions on form E.C. 10. BMJ 1(4753), 292-295 (1952).
13. Woollam DH. Thalidomide disaster considered as an experiment in mammalian teratology. BMJ 2(5299), 236-237 (1962).
14. Kefauver E, Harris O. Kefauver-Harris amendments of October 10, 1962 to Food and Drug and Cosmetic Act. Code Federal Regulation 1962;1.
15. Beck M, Monroe S. The Tylenol scare: the death of seven people who took the drug triggers a nationwide alert - and a hunt for a madman. Newsweek 100(15), 32-36 (1982).
16. Cochrane AL. Effectiveness and Efficiency. Random Reflections on Health Services. Nuffield Provincial Hospitals Trust, London, UK (1972).
17. Cochrane AL. 1931-1971: a critical review with particular reference to the medical profession. In: Medicines for the Year 2000. Teeling-Smith G (Ed.). Office of Health Economics, London, UK, 1-11 (1979).
18. Cook DJ, Guyatt GH, Laupacis A, Sacket DL, Goldberg RJ. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 108(Suppl.), 227S-230S (1995).
19. Doody RS, Stevens JC, Beck C et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 56, 1154-1166 (2001).
20. Brainin M, Barnes M, Baron JC et al. Guideline Standards Subcommittee of the EFNS Scientific Committee. Guidance for the preparation of neurological management guidelines by EFNS scientific task forces- revised recommendations 2004. Eur. J. Neurol. 11, 577-581 (2004).
21. Michaud G, McGowan JL, van der Jagt R, Wells G, Tugwell P. Are therapeutic decisions supported by evidence from health care research? Arch. Intern. Med. 158, 1665-1668 (1998).
22. Evidence-Based Medicine Working Group. Evidence-based medicine. A new approach to teaching the practice of medicine. JAMA 268, 2420-2425 (1992).
23. Lance JW, Goadsby PJ. Mechanism And Management Of Headache, 7th Edition. Elsevier, Butterworth, Heinemann, Oxford, UK (2005).
24. King MM. Dr. John S. Pemberton: originator of Coca-Cola. Pharm. Hist. 29, 85-89 (1987).
25. Horton ST, Peters GA, Blumenthal LS. A new product in the treatment of migraine. Mayo Clin. Proc. 20, 241-248 (1945).
26. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. Sumatriptan International Study Group. J. Neurol. 238(Suppl. 1), S66-S69 (1991).
27. Jenicek M. The hard art of soft science: evidence based medicine, reasoned medicine or both? J. Eval. Clin. Pract. 12, 410-419 (2006).
28. Mulrow CD, Lohr KN. Proof and policy from medical research evidence. J. Health Polit. Policy Law 26, 249-266 (2001).
29. Buetow S, Kenealy T. Evidence-based medicine: the need for a new definition. J. Eval. Clin. Practice 6, 85-92 (2000).
30. Langreth R, Waldholz M. New era of personalized medicine: targeting drugs for each unique genetic profile. Oncologist 4, 426-427 (1999).
31. Fricker J. UK's adopts systematic approach to personalised cancer medicine. Mol. Oncol. 5, 217-219 (2011).
32. Wilffert B, Swen J, Mulder H et al. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics. Int. J. Clin. Pharm. 33, 3-9 (2011).
33. Camilleri E, Jacquin L, Paganelli F, Bonello L. Personalized antiplatelet therapy: review of the latest clinical evidence. Curr. Cardiol. Rep. 13, 296-302 (2011).
34. Brown MJ. Personalised medicine for hypertension. BMJ 343, d4697 (2011).
35. Dowd SE, Wolcott RD, Kennedy J, Jones C, Cox SB. Molecular diagnostics and personalised medicine in wound care: assessment of outcomes. J. Wound Care 20(5), 232, 234-239 (2011).
36. Szefler SJ. Personalised medicine for asthma management in pregnancy. Lancet 378(9795), 963-964 (2011).
37. Zhu WB, Long XY, Fan LQ. Male fecundity prognosis and infertility diagnosis in the era of personalised medicine. Asian J. Androl. 12, 463-467 (2010).
38. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann. Rheum. Dis. 70, 4-7 (2011).
39. Miossec P, Verweij CL, Klareskog L et al. on behalf of the Group for the Respect of Ethics and Excellence in Science (GREES). Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann. Rheum. Dis. 70, 1713-1718 (2011).
40. Thng TG, Lim KS. Personalised medicine for psoriasis: a real possibility ahead. Ann. Acad. Med. Singapore 39, 588-590 (2010).
41. Browman G, Hebert PC, Coutts J, Stanbrook MB, Flegel K, MacDonald N. Personalized medicine: a windfall for science, but what about patients? CMAJ 183(18), E1277 (2011).
42. Clarke A, Thirlaway K. Genetic counselling for personalised medicine. Hum. Genet. 130, 27-31 (2011).
43. Sconce EA, Khan TI, Wynne HA et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
44. Miller WR, Larionov AA. Bridging the gap between translational research and clinical application. J. Natl Cancer Inst. Monogr. 2011, 134-137 (2011).
45. Miller WR, Larionov A, Renshaw L et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J. Clin. Oncol. 27, 1382-1387 (2009).
46. Nebert DW. Given the complexity of the human genome, can 'personalised medicine' or 'individualised drug therapy' ever be achieved? Hum. Genomics 3, 299-300 (2009).
47. Beckett M, Quiter E, Ryan G et al. Bridging the gap between basic science and clinical practice: the role of organizations in addressing clinician barriers. Implement. Sci. 6, 35 (2011).
48. Morgan M, Barry CA, Donovan JL, Sandall J, Wolfe CD, Boaz A. Implementing 'translational' biomedical research: convergence and divergence among clinical and basic scientists. Soc. Sci. Med. 73, 945-952 (2011).
49. McClain DA. Bridging the gap between basic and clinical investigation. Trends Biochem. Sci. 35, 187-188 (2010).
50. Kong HH, Segre JA. Bridging the translational research gap: a successful partnership involving a physician and a basic scientist. J. Invest. Dermatol. 130, 1478-1480 (2010).
51. Restifo LL, Phelan GR. The cultural divide: exploring communication barriers between scientists and clinicians. Dis. Model Mech. 4, 423-426 (2011).
52. Kahn K, Ryan G, Beckett M et al. Bridging the gap between basic science and clinical practice: a role for community clinicians. Implement. Sci. 6, 34 (2011).
53. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst. Rev. (3), CD000029 (2008).
54. Mega JL, Close SL, Wiviott SD et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 Trial: a pharmacogenetic analysis. Lancet 376(9749), 1312-1319 (2010).
55. Limdi NA, Wadelius M, Cavallari L et al. International Warfarin Pharmacogenetics Consortium. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115, 3827-3834 (2010).
56. Sackett DL, Richardson WS, Rosenberg W, Haynes RB (Eds). Evidence-Based Medicine: How to Practice and Teach EBM. Churchill Livingstone, London, UK (1997).
57. Muir Gray JA. Evidence-Based Healthcare. How to Make Health Policy and Management Decisions. Churchill Livingstone, London, UK (1997).
58. Koziol JA. New tricks with old dogs: personalised medicine and clinical trials. Br. J. Cancer 105, 599-601 (2011).
59. Guttmacher AE, McGuire AL, Ponder B, Stefansson K. Personalized genomic information: preparing for the future of genetic medicine. Nat. Rev. Genet. 11, 161-165 (2010).
60. AMP Whole Genome Analysis Working Group. The Association for Molecular Pathology's approach to supporting a global agenda to embrace personalized genomic medicine. J. Mol. Diagn. 13, 249-251 (2011).
61. Swanton C, Burrell RA, Futreal PA. Breast cancer genome heterogeneity: a challenge to personalised medicine? Breast Cancer Res. 13, 104 (2011).
62. Abrahams E. Personalized medicine realizing its promise. Gen. Eng. Biotech. News 29, 70-73 (2009).
63. Timmermans S, Mauck A. The promises and pitfalls of evidence-based medicine. Health Aff. (Millwood) 24, 18-28 (2005).
64. Laurence J. Getting personal: the promises and pitfalls of personalized medicine. Transl. Res. 154, 269-271 (2009).
65. Jenicek M. Evidence-based medicine: fifteen years later. Golem the good, the bad, and the ugly in need of a review? Med. Sci. Monit. 12(11), RA241-RA251 (2006).
66. Khoury MJ. Dealing with the evidence dilemma in genomics and personalized medicine. Clin. Pharmacol. Ther. 87, 635-638 (2010).
67. Kumar D. The personalised medicine. A paradigm of evidence-based medicine. Ann. Ist Super Sanita 47, 31-40 (2011).
68. Sackett DL, Rosenberg WMC. The need for evidence-based medicine. J. R. Soc. Med. 88, 620-624 (1995).
69. Jenicek M. A Physician's Self-Paced Guide to Critical Thinking. American Medical Association (AMA Press), Chicago, IL, USA (2006).
70. Nierenberg AA. Promises, pitfalls, and pleasures of practicing evidence based psychiatry and neurology. CNS Spectr. 14, 12 (2009).
71. Jorgensen JT. New era of personalized medicine: a 10 year anniversary. Oncologist 14(5), 557-558 (2009).